1. Home
  2. BRC vs TGTX Comparison

BRC vs TGTX Comparison

Compare BRC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brady Corporation

BRC

Brady Corporation

HOLD

Current Price

$82.12

Market Cap

4.1B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$33.85

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRC
TGTX
Founded
1914
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.9B
IPO Year
2005
2008

Fundamental Metrics

Financial Performance
Metric
BRC
TGTX
Price
$82.12
$33.85
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$1.20
$49.80
AVG Volume (30 Days)
220.6K
1.6M
Earning Date
05-15-2026
05-04-2026
Dividend Yield
1.20%
N/A
EPS Growth
N/A
1746.67
EPS
N/A
2.77
Revenue
$1,144,698,000.00
$2,785,000.00
Revenue This Year
$7.36
$49.08
Revenue Next Year
$3.57
$26.69
P/E Ratio
$23.35
$12.30
Revenue Growth
5.86
N/A
52 Week Low
$65.76
$25.37
52 Week High
$99.29
$40.99

Technical Indicators

Market Signals
Indicator
BRC
TGTX
Relative Strength Index (RSI) 47.16 49.29
Support Level $76.10 $32.95
Resistance Level $82.71 $35.33
Average True Range (ATR) 2.45 1.28
MACD 0.03 -0.43
Stochastic Oscillator 35.71 13.01

Price Performance

Historical Comparison
BRC
TGTX

About BRC Brady Corporation

Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: